<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Novocure 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=25807></link><description><![CDATA[Novocure 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 15:28:37 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2015/10/3554153577_20151007114300_1230055041.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma]]></title><link>https://www.newswire.co.kr/newsRead.php?no=805618</link><description><![CDATA[ST. HELIER, Jersey--(Business Wire/Korea Newswire)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM). Optune is a portable, non-invasive device that delivers low-intensity, intermediate frequency, alternating electric fields - ref...]]></description><pubDate>Wed, 07 Oct 2015 11:50:00 +0900</pubDate></item><item><title><![CDATA[FDA, 새로 진단되는 교모세포종 치료에 테모졸로미드와 병용투여되는 옵튠 승인]]></title><link>https://www.newswire.co.kr/newsRead.php?no=805619</link><description><![CDATA[세인트 헬리어, 저지--(Business Wire/뉴스와이어)--노보큐어(Novocure)(NASDAQ:NVCR)는 미국 식품의약국(FDA) 교모세포종 진단을 받은 성인 환자 치료용으로 테모졸로미드와 병용투여되는 옵튠을 승인했다고 발표했다. 옵튠은 암세포 복제를 억제하고 암세포 사망을 유발하는 종양 치료장(TTFields)이라고 하는 저강도, 중주파, 교류 전기장을 투여하는 휴대용 비침습 기기이다.   옵튠(Optune) 은 FDA 최초로 승인을 받은 치...]]></description><pubDate>Wed, 07 Oct 2015 11:50:00 +0900</pubDate></item></channel></rss>